

Marcus R Pereira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6804832/publications.pdf>

Version: 2024-02-01

50
papers

2,052
citations

394421

19
h-index

254184

43
g-index

50
all docs

50
docs citations

50
times ranked

4116
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation, 2020, 20, 1800-1808.	4.7	683
2	Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology, 2020, 72, 807-817.	7.3	269
3	Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clinical Infectious Diseases, 2019, 68, 1255-1264.	5.8	137
4	Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplantation, 2015, 21, 1511-1519.	2.4	78
5	Clinical Utilization of the FilmArray Meningitis/Encephalitis (ME) Multiplex Polymerase Chain Reaction (PCR) Assay. Frontiers in Neurology, 2019, 10, 281.	2.4	73
6	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 2083-2088.	4.7	64
7	Effect of Ex Vivo Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques. Transplantation, 2017, 101, 274-283.	1.0	61
8	Genomic Surveillance Reveals Diversity of Multidrug-Resistant Organism Colonization and Infection: A Prospective Cohort Study in Liver Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 905-912.	5.8	60
9	COVID-19 in lung transplant recipients: A single center case series from New York City. American Journal of Transplantation, 2020, 20, 3072-3080.	4.7	54
10	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. American Journal of Transplantation, 2022, 22, 1925-1926.	4.7	54
11	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. American Journal of Transplantation, 2020, 20, 3198-3205.	4.7	48
12	Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study. Transplant Infectious Disease, 2021, 23, e13637.	1.7	47
13	Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. American Journal of Transplantation, 2021, 21, 2254-2261.	4.7	40
14	<i>In Vivo</i> and <i>In Vitro</i> Antimalarial Properties of Azithromycin-Chloroquine Combinations That Include the Resistance Reversal Agent Amlodipine. Antimicrobial Agents and Chemotherapy, 2011, 55, 3115-3124.	3.2	37
15	Heart or lung transplant outcomes in HIV-infected recipients. Journal of Heart and Lung Transplantation, 2019, 38, 1296-1305.	0.6	37
16	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. American Journal of Transplantation, 2022, 22, 2682-2688.	4.7	35
17	Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells. Science Immunology, 2021, 6, .	11.9	28
18	Kidney allograft biopsy findings after COVID-19. American Journal of Transplantation, 2021, 21, 4032-4042.	4.7	24

#	ARTICLE	IF	CITATIONS
19	Methicillin-resistant <i>Staphylococcus aureus</i> in solid organ transplantation” Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13611.	1.6	23
20	Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. <i>Transplantation</i> , 2021, 105, 216-224.	1.0	18
21	Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease. <i>Transplant Infectious Disease</i> , 2021, 23, e13487.	1.7	14
22	SARS-CoV-2 infection increases tacrolimus concentrations in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14193.	1.6	14
23	Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results. <i>American Journal of Transplantation</i> , 2020, 20, 617-619.	4.7	13
24	Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3487-3494.	2.3	12
25	Antivirals for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 355-365.	2.0	12
26	What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. <i>PLoS ONE</i> , 2021, 16, e0249349.	2.5	12
27	Outcomes for potential kidney transplant recipients offered public health service increased risk kidneys: A single-center experience. <i>Clinical Transplantation</i> , 2018, 32, e13427.	1.6	10
28	<i>Clostridioides difficile</i> infection and recurrence among 2622 solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13184.	1.7	10
29	Cycle Thresholds Among Solid Organ Transplant Recipients Testing Positive for SARS-CoV-2. <i>Transplantation</i> , 2021, 105, 1445-1448.	1.0	10
30	Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. <i>Transplant Infectious Disease</i> , 2021, 23, e13542.	1.7	9
31	Prolonged severe acute respiratory syndrome coronavirus 2 persistence, attenuated immunologic response, and viral evolution in a solid organ transplant patient. <i>American Journal of Transplantation</i> , 2022, 22, 649-653.	4.7	9
32	Infectious Complications and Vaccinations in the Posttransplant Population. <i>Medical Clinics of North America</i> , 2016, 100, 587-598.	2.5	8
33	Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	7
34	National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 2010-2019.	5.8	7
35	Febrile neutropenia after kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 3436-3443.	4.7	6
36	The solid organ transplant recipient with SARS-CoV-2 infection. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 412-418.	1.6	5

#	ARTICLE	IF	CITATIONS
37	The evolving threat of carbapenem-resistant infections after liver transplantation: The case of <i>Acinetobacter baumannii</i> . <i>Liver Transplantation</i> , 2016, 22, 579-581.	2.4	4
38	Human Polyomavirus 9: An Emerging Cutaneous and Pulmonary Pathogen in Solid Organ Transplant Recipients. <i>JAMA Dermatology</i> , 2022, 158, 293.	4.1	4
39	Impact of CMV Reactivation, Treatment Approaches, and Immune Reconstitution in a Nonmyeloablative Tolerance Induction Protocol in Cynomolgus Macaques. <i>Transplantation</i> , 2020, 104, 270-279.	1.0	3
40	Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection. <i>Cytotherapy</i> , 2021, 23, 980-984.	0.7	3
41	HIV transmission through living donor kidney transplant: An 11-year follow-up on the recipient and donor. <i>Transplant Infectious Disease</i> , 2021, 23, e13691.	1.7	3
42	One Year Into the Pandemic: Evolving COVID-19 Outcomes in Lung Transplant Recipients, a Single-center Experience. <i>Transplantation Direct</i> , 2022, 8, e1296.	1.6	3
43	Transplanting patients with active bacterial infection. <i>Clinical Liver Disease</i> , 2017, 9, 81-85.	2.1	2
44	Eosinophils, Lymphocytes, and Myocytes, Oh My: HIV-Associated Myocarditis. <i>American Journal of Medicine</i> , 2020, 133, 52-55.	1.5	1
45	The role of gastrointestinal pathogen PCR testing in liver transplant recipients hospitalized with diarrhea. <i>Transplant Infectious Disease</i> , 0, , .	1.7	1
46	Impact of a Surgical Antimicrobial Prophylaxis Change on the Epidemiology of Urine Isolates in Kidney Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
47	Incidence of Infection Following Transplantation in Single- vs Double- Lung Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
48	Reply. <i>Liver Transplantation</i> , 2016, 22, 131-131.	2.4	0
49	Remembrance of a Passing Pandemic. <i>Liver Transplantation</i> , 2021, 27, 1233-1234.	2.4	0
50	Pre-liver Transplant <i>Aspergillus</i> Colonization: An Ounce of Prevention. <i>Transplantation</i> , 2021, 105, 474-475.	1.0	0